Log In
BCIQ
Print this Print this
 

DARA-PH20, subcutaneous daratumumab

  Manage Alerts
Collapse Summary General Information
Company Genmab A/S
DescriptionSubcutaneous daratumumab, a human IgG1k mAb against CD38 that utilizes Enhanze recombinant human PH20 hyaluronidase (rHuPH20) technology
Molecular Target CD38
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationMultiple myeloma (MM)
Indication DetailsTreat relapsed or refractory multiple myeloma (MM)
Regulatory Designation
PartnerHalozyme Therapeutics Inc.;
Johnson & Johnson

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today